NAMD Submits Letter of Support for MACPAC’s Accelerated Approval Pathway Drug Rebate Proposal
On April 7, NAMD sent a letter to the Medicaid and CHIP Payment and Access Commission (MACPAC) supporting their recommendation to enhance Medicaid rebates for prescription drugs approved under the Food and Drug Administration’s accelerated approval pathway.
Rising prescription drug costs are a major budgetary concern for state Medicaid programs, as Medicaid is required to cover any drug that is approved by the Food and Drug Administration (FDA) in exchange for mandatory rebates from drug manufacturers. Drugs that are approved under the FDA’s accelerated approval pathway, which requires less rigorous data, are often particularly expensive and sometimes have unclear clinical benefits. MACPAC recently discussed a recommendation to enhance mandatory rebates for drugs approved under this accelerated pathway.
On behalf of the state Medicaid directors, NAMD wrote a letter of support for this recommendation. Increased rebates would help states afford coverage of these expensive therapies, while also providing an incentive for manufacturers to quickly complete post-marketing clinical trials for these drugs
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
NAMD Urges CMS to Mitigate State Costs on Controversial Alzheimer’s Drug
Drop us your email and we’ll keep you up-to-date on Medicaid issues.